Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients
Schizophrenia Research · 2024-02 · 264 · 471-478
DOI: 10.1016/j.schres.2024.01.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Schizophrenia Research, 2024-02. Verfasst von Marieke van der Pluijm und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, the Netherlands; Department of Psychiatry, Amsterdam UMC, Unive…. Hauptthemen laut MEDLINE: Glutamic Acid, Psychotic Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.
Abstract (Originalsprache)
BACKGROUND: Around 30 % of schizophrenia patients do not respond sufficiently to conventional antipsychotic treatment. Glutamate and γ-aminobutyric acid (GABA) may be implicated in treatment resistant (TR) patients. Some data indicate that TR patients show increased glutamate levels compared to responders, but findings are inconclusive and limited in the early disease stage. Furthermore, the two neurotransmitters have rarely been assessed in conjunction. We therefore aimed to investigate the role of GABA+ and glutamate in first episode TR patients and explore whether these neurometabolites could be potential predictive markers for TR schizophrenia. STUDY DESIGN: We used proton magnetic resonance spectroscopy (MRS) to assess glutamate + glutamine (Glx) and GABA including macromolecules (GABA+) in the anterior cingulate cortex (ACC) of 58 first episode psychosis patients. At six months follow-up treatment response was determined and in a subgroup of 33 patients a follow-up MRS scan was acquired. STUDY RESULTS: Glx and GABA+ levels were not significantly different between TR patients and responders at baseline and the levels did not change at six months follow-up. The groups differed in voxel fractions, which could have influenced our results even though we corrected for these differences. CONCLUSIONS: Our findings do not provide evidence that ACC Glx or GABA+ levels are potential biomarkers for TR in first episode psychosis. Future research needs to take in to account voxel fractions and report potential differences. Comparison with previous literature suggests that illness duration, clozapine responsiveness and medication effects may partly explain the heterogeneous results on Glx and GABA+ levels in TR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, the Netherlands; Department of Psychiatry, Amsterdam UMC, University of Amsterdam, the Netherlands. Electronic address: m.vanderpluij…
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, the Netherlands.
- Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Psychiatry, Amsterdam UMC, University of Amsterdam, the Netherlands.
Förderung
- ZonMw
Zitieren
APA
van der Pluijm, M., Alting, M., Schrantee, A., Edden, R. A. E., Booij, J., de Haan, L., & van de Giessen, E. (2024). Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients. Schizophrenia Research, 264, 471-478. https://doi.org/10.1016/j.schres.2024.01.025
Vancouver
van der Pluijm M, Alting M, Schrantee A, Edden RAE, Booij J, de Haan L, et al. Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients. Schizophrenia Research. 2024;264:471-478. doi:10.1016/j.schres.2024.01.025
BibTeX
@article{vanderPluijm2024,
author = {van der Pluijm, Marieke and Alting, Maartje and Schrantee, Anouk and Edden, Richard A E and Booij, Jan and de Haan, Lieuwe and van de Giessen, Elsmarieke},
title = {Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients},
journal = {Schizophrenia Research},
year = {2024},
volume = {264},
pages = {471--478},
doi = {10.1016/j.schres.2024.01.025}
}
EUVIMED